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CC BY-NC-ND license (http://creativeAbstract The aim of the study was to determine whether serum ischemia-modified albumin
(IMA) levels in patients with carbon monoxide (CO) poisoning were higher compared with a con-
trol group of healthy volunteers. In addition, the study sought to determine if there was a cor-
relation between serum IMA levels and carboxyhemoglobin (COHB) levels and other critical
neurological findings (CNFs). In this prospective study, the IMA levels of 100 patients with CO
poisoning and 50 control individuals were compared. In addition, the IMA and COHB levels were
analyzed according to absence or presence CNFs in patients with CO poisoning. The levels of IMA
(mg/dL) on admittance, and during the 1st hour and 3rd hour, in patients with CO poisoning
(49.90  35.43, 30.21  14.81, and 21.87  6.03) were significantly higher, compared with
the control individuals (17.30 2.88). The levels of IMA in the 6th hour were not higher compared
with control individuals. The levels of IMA on admittance, and during the 1st hour, 3rd hour, and
6th hour, and COHB (%) levels in patients who had CNFs were higher compared with IMA levels and
COHB levels in patients who had no CNFs (p < 0.001). However, when the multivariate model
was created, it was observed that IMA level on admittance was a poor indicator for prediction
of CNFs (odds ratio Z 1.05; 95% confidence interval, 1.01e1.08). We therefore concluded that
serum IMA levels could be helpful in the diagnosis of CO poisoning. However, we believe that IMA
levels cannot be used to predict which patients will develop CNFs due to CO poisoning.
Copyright ª 2016, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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Carbon monoxide (CO) poisoning causes hypoxia because
the CO molecule binds to hemoglobin with high affinity
(230e270 times more than that of oxygen), reduces the
oxygen-carrying capacity of the blood, and finally impairs
delivery of the oxygen to tissue. Both the early and late
complications of acute CO poisoning are responsible for its
significant mortality rate [1]. In most patients, the central
nervous system (CNS) is affected, and the clinical effects of
CO poisoning on the CNS can be diverse, such as headache,
dizziness, seizure, confusion, and coma [2]. Because it is
unclear whether carboxyhemoglobin (COHB) levels corre-
late with clinical severity, there is clearly a need for a novel
biochemical marker such as ischemia-modified albumin
(IMA).
Human serum albumin converts to IMA when the N ter-
minus of albumin is altered because of oxidative stress or
ischemia. It has been found that serum IMA levels were
significantly higher in patients with acute coronary syn-
drome, pulmonary embolism, stroke and cerebral hemor-
rhage, mesenteric ischemia, and peripheral vascular
disease [3].
The aim of the study was to determine whether serum
IMA levels in patients with CO poisoning were higher
compared with a control group of healthy volunteers. In
addition, the study sought to determine if there was a
correlation between serum IMA levels and COHB levels and
other critical neurological findings (CNFs).
Methods
This prospective study was conducted between September
2010 and April 2011 in the emergency department (ED) of a
training and research hospital in Ankara, Turkey. Approval
for the study was obtained from the hospital’s committee
on ethics, and patients were required to sign an informed
consent form before they were enrolled.
The study included the first 100 patients who were
admitted to the ED because of CO poisoning. The selection
criteria were as follows: patients aged 18 years or older
with CO poisoning and the absence of any of the exclusion
criteria (Table 1). CO poisoning was defined as levels of
COHB that exceeded 5% for nonsmokers and 10% for
smokers in patients who has symptoms consistent with CO
poisoning such as headache, vomiting, nausea, dizziness,
syncope, altered state of consciousness, dysarthria, palpi-
tation, dyspnea, and chest pain. Fifty control individuals
were selected from healthy volunteers who had no coronary
artery disease, peripheral artery disease, or acute mesen-
teric ischemia.
On admission, all patients with CO poisoning were
evaluated by an emergency physician, and demographic
details, findings of the physical examination, and labora-
tory results of the patients were recorded. All patients
were treated with normobaric 100% oxygen treatment with
reservoir mask for 6 hours. The criteria for hyperbaric ox-
ygen (HBO) treatment were as follows: COHB levels higher
than 25%; patients with syncope, seizure, focal neurological
deficit, coma, confusion, or evidence of acute myocardial
ischemia. Included as CNFs were seizure, altered state ofconsciousness, syncope, focal neurological deficit, coma,
and Glasgow coma score (GCS) less than 15 on admission.
Measurement of IMA levels was conducted using venous
blood samples from the antecubital region taken on
admittance, and subsequently during the 1st hour, 3rd hour,
and 6th hour after admittance. In addition, venous blood
gas analysis, including COHB levels and biochemical values,
was performed routinely on every patient upon
admittance.
Specimens taken to measure IMA levels were stored for
30 minutes at room temperature and then centrifuged at
3500 rpm for 5 minutes. Samples were then transferred to
Eppendorf tubes and stored at 80C until analysis. All
specimens were analyzed using an Albumin Cobalt Binding
test. This test was performed by adding 50 mL 0.1% cobalt
(II) chloride (CoCl2,6H2O) (Sigma-Aldrich Chemie GmbH
Riedstrasse 2, Steinheim, Germany) to the patient serum.
After mixing, followed by 10 minutes of incubation to allow
for albumin cobalt binding, 50 mL 1.5 mg/mL dithiothreitol
was added. After mixing followed by 2 minutes of incuba-
tion, 1.0 mL of a 0.9% sodium chloride solution was added in
order to reduce the binding capacity. The blank was pre-
pared similarly with distilled water instead of dithio-
threitol. The absorbance of samples was measured at
470 nm using a spectrophotometer (Jenway 6315 UV/visible
Scanning Spectrophotometers, United Kingdom). Results
were expressed in mg/dL.
All data were analyzed with the SPSS for Windows
version 17 (SPSS, Chicago, IL, USA). Demographic features,
clinical symptoms, physical examination findings, and lab-
oratory results of the study group were expressed as
median standard deviation and as percentage.
A KolmogoroveSmirnov test was used to evaluate
whether the categorical variables were normally distrib-
uted. It was determined that the parameters were not
homogeneously distributed; therefore, nonparametric tests
were used. The ManneWhitney U test was used to compare
the study and the control group with the help of the chosen
parameters. A paired t test was used to analyze IMA level
changes on admittance, as well as in the 1st hour, 3rd hour,
and 6th hour. Pearson’s correlation test was used to state
the relationship between IMA levels in the control group on
admittance and the chosen parameters.
A univariate logistic regression model was constructed to
assess the factors predicting CNFs in patients with CO
poisoning. Each independent variable was tested in the
univariable model, and those that were significant were
then tested in the multivariable model. Multivariate logistic
regression analyses were conducted only for variables that
were statistically significant at p < 0.1 level in the uni-
variate model.Results
The study group included 57 females (57%) and 43 males
(43%). The control group comprised 30 females (60%) and 20
males (40%). The median age of the study group was 32
[interquartile range (IQR)25e75% Z 23e46] years. The
median age of the control group was 29
(IQR25e75% Z 22e38) years. The median age and sex
percentages of the two groups were similar (p > 0.05).
Table 1 Exclusion criteria.
 Age, < 18 y
 Patients with coronary artery disease, peripheral
arterial disease, acute mesenteric ischemia, & acute
ischemic cerebrovascular disease
 Patients with severe heart or liver failure
 Albumin level, <3.5 g/dL & >5.5 g/dL
 Pregnant patients
 Patients who refused to be involved in the study
 Patients in cardiopulmonary arrest on admission
Ischemia-modified albumin in CO poisoning 203The levels of IMA on admittance, and during the 1st hour
and 3rd hour, in patients with CO poisoning (49.90  35.43,
30.21  14.81, and 21.87  6.03) were significantly higher
compared with those of the control individuals
(17.30  2.88). The levels of IMA in the 6th hour were not
significantly higher compared with those of the control in-
dividuals. IMA levels were decreased significantly at the 1st
hour, 3rd hour, and 6th hour from previous levels (p < 0.001
for all measurements; Tables 2 and 3).
The most common symptoms in the study group were
headache (81%) and nausea (71%). Twenty-two of all pa-
tients (22%) had CNFs, which were syncope (18%), altered
state of consciousness (15%), and GCS less than 15 (12%).
Demographic and some laboratory data of the study group
are shown in Table 3. When we analyzed IMA levels ac-
cording to the GCS of patients, IMA levels were observed to
be higher in patients who had GCS< 15 than those of pa-
tients whose GCS was 15 (Table 4).
Although these 22 patients had HBO treatment in-
dications, only six patients could be treated with HBO
because of technical inadequacy. Only two of 22 patients
were admitted to the intensive care unit for 48 hours, and
at the end of this time they were discharged.
The levels of IMA on admittance and the first hours, and
COHB levels in patients who had CNFs were significantly
higher compared with the IMA levels and COHB levels in
patients who had no CNFs (p < 0.001). However, the levels
of IMA on 3rd hour and 6th hour were not significantly higher
(Table 3). In addition, it was found that serum levels of IMA
on admittance correlated with COHB levels on admittance
in patients with CO poisoning (r Z 0.427, p < 0.001).
To create a multivariate model, variables that were
statistically significant at p < 0.1 level in the univariate
model (age, respiratory rate, white blood cell, sodium,
potassium, alanine transaminase, COHB levels, and IMA)




At admittanced1st h 16.5  19.3 12.5e20.4 <0.001
1ste3rd h 8.3  10.6 6.1e10.3 <0.001
3rde6th h 3.2  2.9 2.6e3.8 <0.001
CI Z confidence interval; IMA Z ischemia-modified albumin;
SD Z standard deviation.the HosmereLemeshow test was performed and the fit of
the model was determined to be good (p Z 0.68). The
multivariate analysis results revealed that only IMA level at
admittance was an indicator for prediction of CNFs
[pZ 0.002; odds ratio (OR)Z 1.05; 95% confidence interval
(CI), 1.01e1.08; Table 5].Discussion
The CNS is one of the most affected body systems by hyp-
oxia due to CO poisoning. The human brain, in particular, is
the organ most sensitive to hypoxia. Therefore, the most
severedas well as the nonseveredsymptoms seen on
admittance affected the CNS such as headache, dizziness,
seizure, confusion, loss of consciousness, and coma [1]. In
clinical practice, although COHB levels are used for diag-
nosis and prediction of the severity of CO poisoning, it is
unclear whether there is a correlation between clinical
severity and COHB levels. In a study conducted by Hampson
and Hauff [4], which evaluated the correlation between
COHB levels and clinical severity, it was reported that there
is no correlation between these parameters from a clinic
standpoint. By contrast, C¸evik et al [5] evaluated the
relationship between the poisoning severity score (PSS) and
COHB levels and found that a moderate correlation exists
between PSS grades and COHB levels. COHB levels of Grade
3 (severe), in particular, were significantly different from
other grades [5].
Because of this uncertainty, there is a need for a new
biochemical marker that can be used for prediction of the
severity and diagnosis of CO poisoning. In previous studies,
alternate markers were investigated, such as neuron-
specific enolase (NSE), S100B protein, and tau protein. In
a study conducted by Yardan et al [6], which looked at the
levels of NSE and S100B protein in patients with CO
poisoning, it was found that although S100B protein levels
in patients were higher than those in control individuals,
there was no difference between the patient group and
control individuals in terms of NSE. In addition, the S100B
and NSE values were significantly higher in unconscious
than in conscious patients [6]. In another similar study,
Cakir et al [7] attempted to determine whether levels of
S100B and NSE changed in CO poisoning-related brain
injury. Their findings have shown that although S100B
levels correlated strongly with GCS in patients, NSE levels
showed no such correlation [7]. In another study,
Kılıc¸aslan et al [8] reported that tau protein levels were
significantly higher in patients who were admitted with CO
poisoning and severe neurological findings; however, ac-
cording to the authors, this difference did not reach
clinical significance.
IMA is one of the new markers that was investigated in
patients with CO poisoning. Previous studies have shown
that IMA levels can increase in many ischemic diseases such
as pulmonary embolism, acute mesenteric ischemia, deep
venous thrombosis, acute coronary syndromes, ischemic
stroke, intracerebral hemorrhage, subarachnoid hemor-
rhage, and seizure [9e15]. To our knowledge, in the English
literature, there are two studies that evaluated the rela-
tionship of CO poisoning and IMA levels. The first of these
studies is an animal study conducted by Turedi et al [16] in









Age (y) 31.8 (18e60) 41 (25e53) 30 (23e43) 0.09a
Sex: female, n (%) 30 (60) 13 (59) 44 (56) 0.8
Vital signs
 Systolic blood pressure (mmHg) 115 (111e126) 120 (116e132) 120 (110e130) 0.2
 Diastolic blood pressure (mmHg) 79 (70e85) 80 (70e90) 80 (70e80) 0.7
 Heart rate (beat/min) 85 (80e90) 90 (70e110) 86 (78e98) 0.5
 Respiratory rate 16 (15e17) 19 (17e22) 17 (16e18) 0.01a
 Oxygen saturation 98 (97e99) 98 (97e99) 98 (97e99) 0.6
Laboratory results
 White blood cell count (103/mm3) 8.5 (7.0e9.5) 11.4 (8.1e16) 8.1 (7.1e10.4) 0.001a
 Hemoglobin (g/dL) 13.1 (12.5e16) 13.3 (12.2e15.2) 13.4 (12.5e14) 0.8
 Creatinine (mg/dL) 0.8 (0.8e1.0) 1.0 (0.9e1.1) 0.9 (0.8e1.0) 0.06a
 Sodium (mmol/L) 140 (138e140) 140 (138e140) 139 (137e141) 0.1
 Potassium (mmol/L) 4.0 (3.7e4.0) 4.1 (3.8e4.8) 4.0 (3.7e4.1) 0.1
 Alanine transaminase (UI/L) 18 (15e25) 20 (16e37) 18 (14e25) 0.1
 Aspartate aminotransferase (UI/L) 20 (18e22) 21 (17e32) 20 (17e24) 0.3
 Albumin (g/dL) 4.7 (4.5e4.8) 4.7 (4.3e5.0) 4.7 (4.3e5.0) 0.9
_IMA and COHB levels (mean  SD)
 COHB levels (%) d 26.9  8.9 22.1  5.9 0.02
 IMA at admittance 17.30  2.88 89.8  53.1 38.6  16.1 <0.001b
 IMA at 1st h d 45.3  20.9 27.2  10.8 <0.001
 IMA at 3rd h d 26.0  7.4 21.0  5.3 0.07
 IMA at 6th h d 21.6  5.4 18.0  4.0 0.06
COHB Z carboxyhemoglobin; IMA Z ischemia-modified albumin; IQR Z interquartile range; SD Z standard deviation.
a These differences were attributed to the group of patients with CNFs.
b This difference was detected between all groups.
Table 4 Comparison of serum IMA (mg/dL) levels according to GCS of patients.
GCS 15 GCS 14e13 GCS < 13 p
On admittance 35 (27e48) 127 (96e158) 95 (69e160) <0.001a
1st h 26 (21e31) 52 (45e76) 53 (49e117) <0.001b
3rd h 17 (15e20) 29 (26e39) 32 (26e62) <0.001b
6th h 18 (16e20) 25 (22e28) 26 (15e43) 0.004b
GCS Z Glasgow coma score; IMA Z ischemia-modified albumin.
a This difference was detected between all groups.
b These differences were detected between patients with GCS group and other groups.
204 M. Das‚ et al.2013. In this study, 18 rats were randomized into three
groups. Group 1 served as the control group. Group 2 con-
sisted of rats with low-dose exposure to CO, and Group 3
consisted of rats with high-dose CO exposure. At the end of
30 minutes, laparotomy was performed on all rats under
general anesthesia, and blood samples were collected from
the abdominal aorta for IMA and COHB measurement. In
addition, specimens of brain, heart, kidney, liver, and lung
were collected to determine organ damage. When results
were analyzed, they found that serum IMA levels rose
significantly in Groups 2 and 3 (CO exposure) over Group 1
(control group). In addition, they found a significant posi-
tive correlation between COHB and IMA levels (r Z 0.51,
p Z 0.03) in rats with exposure to CO. However, resultshave shown that there was no correlation between organ
damage and IMA levels. Finally, the study found that serum
IMA levels could be helpful for diagnosis of CO poisoning as
a supplementary diagnostic tool, in addition to COHB
levels; however, IMA levels were not found to be good
biochemical parameters for determining the severity of CO
poisoning [16].
In a second study, Turedi et al [17] compared 33 patients
who were admitted for CO poisoning with 44 control in-
dividuals in terms of IMA levels. The researchers attempted
to determine whether IMA levels measured in the 3rd hour
decreased compared to IMA levels on admittance. They
reported that mean IMA levels were statistically signifi-
cantly higher in the CO poisoning group than in the control
Table 5 Multivariate logistic regression to predict critical
neurological findings.
Wald p OR (95% CI)
Age 0.133 0.7 1.009 (0.9e1.06)
Respiratory rate 0.070 0.7 1.02 (0.8e1.2)
WBC 5.673 0.01 1.00 (1.00e1.001)
ALT 0.167 0.6 1.004 (0.9e1.02)
Na 0.013 0.9 1.01 (0.7e1.3)
K 0.041 0.8 1.2 (0.1e8.4)
COHB 0.412 0.5 1.03 (0.9e1.1)
IMA levels admittance 9.474 0.002 1.05 (1.01e1.08)
ALT Z alanine transaminase; CI Z confidence interval;
COHB Z carboxyhemoglobin; IMA Z ischemia-modified albu-
min; K Z potassium; Na Z sodium; OR Z odds ratio;
WBC Z white blood cell count.
Ischemia-modified albumin in CO poisoning 205group. These results are similar to the results of the first
animal study. However, there was no significant decrease of
IMA levels in the 3rd hour compared to IMA levels on
admittance (p Z 0.9). Contrary to the results of the first
study, they did not find any correlation between IMA levels
and COHB levels (0.197; p Z 0.273; 95% CI,
0.157e0.505). Finally, the study attempted to determine
whether there was any difference in IMA levels relative to a
patient’s PSS. No difference in IMA levels was found be-
tween PSS grades of [17].
In our study, we found that IMA levels on admittance
and during the 1st hour and 3rd hour were higher in patients
with CO poisoning than in control individuals. We also
found that serum levels of IMA on admittance correlated
with COHB levels on admittance in patients with CO
poisoning. Although this finding is similar to the results of
the first study, it opposes the results of the second study.
Contrary to the second study, our study has shown that IMA
levels significantly decreased during the 1st hour, 3rd hour,
and 6th hour from previous levels. Finally, IMA levels in
patients with CO poisoning dropped the same value as
those of the control group after 6 hours. In patients with
CO poisoning and treated with 100% oxygen at atmospheric
pressure, the COHB half-life is w75 minutes [18]. Our re-
sults suggested that the half-life values of IMA levels are
relatively longer than those of COHB (w180 minutes).
Thus, we believe that especially for selected patients with
delayed admission to the ED and who were treated with
100% oxygen, IMA levels may be helpful in diagnosis of CO
poisoning based on these results and those of previous
studies.
In addition, our study has shown that IMA levels on
admittance and the 1st hour in patients who have CNFs were
significantly higher than the IMA levels in patients who have
no CNFs. However, when the multivariate model was
created, it was observed that IMA level on admittance was
a poor indicator for prediction of CNFs (ORZ 1.05; 95% CI,
1.01e1.08). Similar to this finding, the results of the first
animal studies (e.g., the results of Turedi et al [16,17])
have shown that there was no correlation between organ
damage and IMA levels. Therefore, we believe that IMA
levels cannot be used to predict which patients will develop
CNFs due to CO poisoning.Limitations
The most important limitation of this study was that the
endpoint of this study was based only on clinical evaluation,
and not on histopathological data or other related data of
the brain injury. In addition, this clinical evolution included
only short-term neurological findings, and not delayed
neurologic sequelae. Another limitation of this study was
that there is no clear description of the onset time of CO
poisoning; thus, the time-dependent change in IMA levels
varied from patient to patient. However, we believe that it
is not easy to overcome this limitation in human studies.
Because CO poisoning generally occurs during nighttime and
when the patients are asleep, making certain of the onset
time of CO poisoning is rather difficult. These limitations
may have weakened the power of our results and our study.Conclusion
The results of this study have shown that the IMA levels of
the study group on admittance were significantly higher
than those of the control group. It was also noted that the
IMA levels of patients who had CNFs were significantly
higher than those of patients who did not have CNFs. We
conclude that serum IMA levels could be helpful in the
diagnosis of CO poisoning in selected patientsdthose with
delayed admission to the ED and who were treated with
100% oxygen. However, we believe that IMA levels cannot
used be to predict which patients will develop CNFs due to
CO poisoning. In addition, the endpoint of our study was
based only on clinical evaluation, and not histopathological
data or other related data of the brain injury. Therefore,
additional studies involving larger groups of participants are
necessary to obtain more accurate results.References
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